# Neurogene Inc.: overview NGNE · Nasdaq · CIK 1404644 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/ngne.md) · [Financials](/companies/ngne/financials.md) · [Filings](/companies/ngne/filings.md) · [Insiders](/companies/ngne/insiders.md) Latest reported revenue: [$0](/filings/0001404644-26-000019.md) for Q4 FY2025, three months to 2025-12-31, from the 10-K filed Mar 24, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001404644-26-000019). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.0](/filings/0001404644-25-000101.md) | [0.0 d](/filings/0001404644-26-000019.md) | not reported | [0.0](/filings/0001404644-25-000081.md) | [0.0](/filings/0001404644-25-000101.md) | [0.0 d](/filings/0001404644-26-000019.md) | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(1.19)](/filings/0001404644-25-000101.md) | not reported | [(1.08)](/filings/0001404644-26-000037.md) | [(1.05)](/filings/0001404644-26-000059.md) | [(0.99)](/filings/0001404644-25-000101.md) | not reported | [(1.39)](/filings/0001404644-26-000037.md) | [(1.53)](/filings/0001404644-26-000059.md) | | Free cash flow | $m | [(15.7) d](/filings/0001404644-25-000101.md) | [(17.6) d](/filings/0001404644-26-000019.md) | [(21.6)](/filings/0001404644-26-000037.md) | [(19.6) d](/filings/0001404644-26-000059.md) | [(19.6) d](/filings/0001404644-25-000101.md) | [(17.6) d](/filings/0001404644-26-000019.md) | [(26.4)](/filings/0001404644-26-000037.md) | [(24.1) d](/filings/0001404644-26-000059.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | [0.0](/filings/0001404644-25-000012.md) | [0.9](/filings/0001404644-26-000019.md) | [0.0](/filings/0001404644-26-000019.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | [(8930.3%)](/filings/0001404644-26-000019.md) | not reported | | Net margin | % | not reported | not reported | not reported | [(8123.7%)](/filings/0001404644-26-000019.md) | not reported | | Diluted EPS | $ per share | [(1.10)](/filings/0001628280-23-008602.md) | [(1.04)](/filings/0001628280-23-008602.md) | not reported | [(4.28)](/filings/0001404644-26-000019.md) | [(4.24)](/filings/0001404644-26-000019.md) | | Free cash flow | $m | [(50.8)](/filings/0001628280-23-008602.md) | [(55.1)](/filings/0001404644-24-000020.md) | [(51.7)](/filings/0001404644-25-000012.md) | [(71.4)](/filings/0001404644-26-000019.md) | [(78.4)](/filings/0001404644-26-000019.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ngne/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [SAMSARA BIOCAPITAL, LLC](/funds/1744967.md) | 2026-06-30 | $54.0m | 1,717,127 | | Unchanged | | [Casdin Capital, LLC](/funds/1534261.md) | 2026-06-30 | $48.6m | 1,545,361 | | Added +125,000 | | [Redmile Group, LLC](/funds/1425738.md) | 2026-06-30 | $44.4m | 1,412,199 | | Reduced −47,400 | | [RTW INVESTMENTS, LP](/funds/1493215.md) | 2026-06-30 | $42.8m | 1,362,456 | | Unchanged | | [EcoR1 Capital, LLC](/funds/1587114.md) | 2026-06-30 | $40.0m | 1,271,342 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $33.3m | 1,057,983 | | Added +52,913 | | [BAKER BROS. ADVISORS LP](/funds/1263508.md) | 2026-06-30 | $31.2m | 991,691 | | Unchanged | | [Balyasny Asset Management L.P.](/funds/1218710.md) | 2026-06-30 | $25.7m | 818,706 | | Added +100,317 | | [Trails Edge Capital Partners, LP](/funds/2077247.md) | 2026-06-30 | $22.5m | 714,885 | | Reduced −67,902 | | [TORONTO DOMINION BANK](/funds/947263.md) | 2026-06-30 | $21.4m | 681,337 | | Unchanged | ## Recent filings [All 723 filings](/companies/ngne/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-11 | 20:57 ET | [10-Q](/filings/0001404644-26-000059.md) | Quarterly report, period 2026-06-30 | 0001404644-26-000059 | | 2026-08-11 | 11:32 ET | [8-K](/filings/0001404644-26-000056.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001404644-26-000056 | | 2026-07-02 | 00:02 ET | [8-K](/filings/0001404644-26-000050.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001404644-26-000050 | | 2026-06-29 | 12:00 ET | [8-K](/filings/0001404644-26-000046.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001404644-26-000046 | | 2026-06-08 | 11:32 ET | [8-K](/filings/0001404644-26-000044.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001404644-26-000044 | | 2026-06-04 | 20:41 ET | [8-K](/filings/0001404644-26-000040.md) | 5.07 Shareholder vote results | 0001404644-26-000040 | | 2026-05-12 | 20:06 ET | [8-K](/filings/0001404644-26-000038.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001404644-26-000038 | | 2026-05-12 | 20:04 ET | [10-Q](/filings/0001404644-26-000037.md) | Quarterly report, period 2026-03-31 | 0001404644-26-000037 | | 2026-04-20 | 11:32 ET | [8-K](/filings/0001404644-26-000030.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001404644-26-000030 | | 2026-04-16 | 20:15 ET | [DEF 14A](/filings/0001404644-26-000027.md) | Proxy statement, period 2026-06-03 | 0001404644-26-000027 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001404644-26-000019.md), filed Mar 24, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1404644 - Tickers: NGNE - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: not reported - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.